{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:02:29Z","timestamp":1740142949631,"version":"3.37.3"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00508-020-01761-3","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T23:05:18Z","timestamp":1605827118000},"page":"52-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Austrian recommendations for the management of essential thrombocythemia"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7369-9700","authenticated-orcid":false,"given":"Veronika","family":"Buxhofer-Ausch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Heibl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer","family":"Sliwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Beham-Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Theresa","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"issue":"2","key":"1761_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ajh.23895","volume":"90","author":"A Tefferi","year":"2015","unstructured":"Tefferi\u00a0A, Barbui\u00a0T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162\u201373. https:\/\/doi.org\/10.1002\/ajh.23895.","journal-title":"Am J Hematol"},{"issue":"3","key":"1761_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620715580068","volume":"6","author":"G Birgeg\u00e5rd","year":"2015","unstructured":"Birgeg\u00e5rd\u00a0G. Advances and challenges in the management of essential thrombocythemia. Ther Adv Hematol. 2015;6(3):142\u201356. https:\/\/doi.org\/10.1177\/2040620715580068.","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"1761_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ajh.25303","volume":"94","author":"A Tefferi","year":"2019","unstructured":"Tefferi\u00a0A, Barbui\u00a0T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94(1):133\u201343. https:\/\/doi.org\/10.1002\/ajh.25303.","journal-title":"Am J Hematol"},{"key":"1761_CR4","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi\u00a0S, Tefferi\u00a0A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a\u00a0literature review of incidence and risk factors. Blood Cancer\u00a0J. 2015;5:e366. https:\/\/doi.org\/10.1038\/bcj.2015.95.","journal-title":"Blood Cancer J"},{"issue":"26","key":"1761_CR5","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui\u00a0T, Finazzi\u00a0G, Carobbio\u00a0A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128\u201333. https:\/\/doi.org\/10.1182\/blood-2012-07-444067. quiz 5252.","journal-title":"Blood"},{"issue":"5","key":"1761_CR6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/leu.2015.360","volume":"30","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger\u00a0H, Jeryczynski\u00a0G, Gisslinger\u00a0B, et\u00a0al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30(5):1126\u201332. https:\/\/doi.org\/10.1038\/leu.2015.360.","journal-title":"Leukemia"},{"issue":"7","key":"1761_CR7","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi\u00a0AM, Antonioli\u00a0E, Guglielmelli\u00a0P, Pardanani\u00a0A, Tefferi\u00a0A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a\u00a0critical reappraisal. Leukemia. 2008;22(7):1299\u2013307. https:\/\/doi.org\/10.1038\/leu.2008.113.","journal-title":"Leukemia"},{"issue":"4","key":"1761_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000140629","volume":"119","author":"A Tefferi","year":"2008","unstructured":"Tefferi\u00a0A. Mutant molecules of interest in myeloproliferative neoplasms: introduction. Acta Haematol. 2008;119(4):192\u20133. https:\/\/doi.org\/10.1159\/000140629.","journal-title":"Acta Haematol"},{"issue":"5","key":"1761_CR9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n\u00a0A, Bellosillo\u00a0B, Pereira\u00a0A, et al. JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol. 2014;89(5):517\u201323. https:\/\/doi.org\/10.1002\/ajh.23676.","journal-title":"Am J Hematol"},{"issue":"25","key":"1761_CR10","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl\u00a0T, Gisslinger\u00a0H, Harutyunyan\u00a0AS, et\u00a0al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N\u00a0Engl J Med. 2013;369(25):2379\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1311347.","journal-title":"N Engl J Med"},{"issue":"10","key":"1761_CR11","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi\u00a0E, Pietra\u00a0D, Ferretti\u00a0V, et\u00a0al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351. https:\/\/doi.org\/10.1182\/blood-2013-11-539098.","journal-title":"Blood"},{"issue":"12","key":"1761_CR12","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1038\/leu.2014.148","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi\u00a0A, Wassie\u00a0EA, Lasho\u00a0TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014;28(12):2300\u20133. https:\/\/doi.org\/10.1038\/leu.2014.148.","journal-title":"Leukemia"},{"issue":"1","key":"1761_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer\u00a0PA, Campbell\u00a0PJ, Scott\u00a0LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT\u20111 cohort. Blood. 2008;112(1):141\u20139. https:\/\/doi.org\/10.1182\/blood-2008-01-131664.","journal-title":"Blood"},{"issue":"3","key":"1761_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","volume":"112","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi\u00a0AM, Antonioli\u00a0E, Guglielmelli\u00a0P, et\u00a0al. Characteristics and clinical correlates of MPL 515W\u3009L\/K mutation in essential thrombocythemia. Blood. 2008;112(3):844\u20137. https:\/\/doi.org\/10.1182\/blood-2008-01-135897.","journal-title":"Blood"},{"issue":"1","key":"1761_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi\u00a0A, Lasho\u00a0TL, Guglielmelli\u00a0P, et\u00a0al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21\u201330. https:\/\/doi.org\/10.1182\/bloodadvances.2016000216.","journal-title":"Blood Adv"},{"issue":"4","key":"1761_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1055\/s-2007-976165","volume":"33","author":"A Tefferi","year":"2007","unstructured":"Tefferi\u00a0A, Elliott\u00a0M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313\u201320.","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"1761_CR17","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","volume":"121","author":"H Gisslinger","year":"2013","unstructured":"Gisslinger\u00a0H, Gotic\u00a0M, Holowiecki\u00a0J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a\u00a0randomized controlled trial. Blood. 2013;121(10):1720\u20138. https:\/\/doi.org\/10.1182\/blood-2012-07-443770.","journal-title":"Blood"},{"issue":"1","key":"1761_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/bjh.14202","volume":"179","author":"V Buxhofer-Ausch","year":"2017","unstructured":"Buxhofer-Ausch\u00a0V, Gisslinger\u00a0B, Schalling\u00a0M, et al. Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. Br J Haematol. 2017;179(1):166\u20139. https:\/\/doi.org\/10.1111\/bjh.14202.","journal-title":"Br J Haematol"},{"key":"1761_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1182\/blood-2018-99-109715","volume":"132","author":"A Tefferi","year":"2018","unstructured":"Tefferi\u00a0A, Guglielmelli\u00a0P, Lasho\u00a0TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythemia (MIPSS-ET) and polycythemia Vera (MIPSS-PV). Blood. 2018;132:578. https:\/\/doi.org\/10.1182\/blood-2018-99-109715.","journal-title":"Blood"},{"issue":"15","key":"1761_CR20","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld\u00a0J, Nangalia\u00a0J, Baxter\u00a0EJ, et\u00a0al. Classification and personalized prognosis in myeloproliferative neoplasms. N\u00a0Engl J Med. 2018;379(15):1416\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1716614.","journal-title":"N Engl J Med"},{"issue":"21","key":"1761_CR21","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele\u00a0J, Kvasnicka\u00a0HM, M\u00fcllauer\u00a0L, Buxhofer-Ausch\u00a0V, Gisslinger\u00a0B, Gisslinger\u00a0H. Essential thrombocythemia versus early primary myelofibrosis: a\u00a0multicenter study to validate the WHO classification. Blood. 2011;117(21):5710\u20138. https:\/\/doi.org\/10.1182\/blood-2010-07-293761.","journal-title":"Blood"},{"issue":"23","key":"1761_CR22","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui\u00a0T, Thiele\u00a0J, Passamonti\u00a0F, et\u00a0al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J\u00a0Clin Oncol. 2011;29(23):3179\u201384. https:\/\/doi.org\/10.1200\/JCO.2010.34.5298.","journal-title":"J Clin Oncol"},{"key":"1761_CR23","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui\u00a0T, Thiele\u00a0J, Vannucchi\u00a0AM, Tefferi\u00a0A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer\u00a0J. 2015;5:e337. https:\/\/doi.org\/10.1038\/bcj.2015.64.","journal-title":"Blood Cancer J"},{"issue":"20","key":"1761_CR24","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"issue":"2","key":"1761_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi\u00a0G, Mesa\u00a0RA, Thiele\u00a0J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a\u00a0consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437\u20138.","journal-title":"Leukemia"},{"issue":"22","key":"1761_CR26","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","volume":"117","author":"A Carobbio","year":"2011","unstructured":"Carobbio\u00a0A, Thiele\u00a0J, Passamonti\u00a0F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117(22):5857\u20139. https:\/\/doi.org\/10.1182\/blood-2011-02-339002.","journal-title":"Blood"},{"issue":"10","key":"1761_CR27","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno\u00a0G, Mannarelli\u00a0C, Guglielmelli\u00a0P, et\u00a0al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552\u20135. https:\/\/doi.org\/10.1182\/blood-2013-11-538983.","journal-title":"Blood"},{"issue":"16","key":"1761_CR28","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1182\/blood-2014-08-596676","volume":"124","author":"G Finazzi","year":"2014","unstructured":"Finazzi\u00a0G, Carobbio\u00a0A, Guglielmelli\u00a0P, et\u00a0al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124(16):2611\u20132. https:\/\/doi.org\/10.1182\/blood-2014-08-596676.","journal-title":"Blood"},{"key":"1761_CR29","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui\u00a0T, Vannucchi\u00a0AM, Buxhofer-Ausch\u00a0V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer\u00a0J. 2015;5:e369. https:\/\/doi.org\/10.1038\/bcj.2015.94.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1761_CR30","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","volume":"116","author":"A Alvarez-Larr\u00e1n","year":"2010","unstructured":"Alvarez-Larr\u00e1n\u00a0A, Cervantes\u00a0F, Pereira\u00a0A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205\u201310. https:\/\/doi.org\/10.1182\/blood-2010-01-263319. quiz 1387.","journal-title":"Blood"},{"issue":"6","key":"1761_CR31","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/bjh.12321","volume":"161","author":"A Alvarez-Larr\u00e1n","year":"2013","unstructured":"Alvarez-Larr\u00e1n\u00a0A, Pereira\u00a0A, Arellano-Rodrigo\u00a0E, Hern\u00e1ndez-Boluda\u00a0JC, Cervantes\u00a0F, Besses\u00a0C. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol. 2013;161(6):865\u201371. https:\/\/doi.org\/10.1111\/bjh.12321.","journal-title":"Br J Haematol"},{"issue":"8","key":"1761_CR32","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/09537100600758677","volume":"17","author":"JJ Michiels","year":"2006","unstructured":"Michiels\u00a0JJ, Berneman\u00a0Z, Schroyens\u00a0W, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a\u00a0distinct aspirin-responsive and coumadin-resistant arterial thrombophilia. Platelets. 2006;17(8):528\u201344.","journal-title":"Platelets"},{"issue":"15","key":"1761_CR33","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","volume":"119","author":"S Pascale","year":"2012","unstructured":"Pascale\u00a0S, Petrucci\u00a0G, Dragani\u00a0A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595\u2013603. https:\/\/doi.org\/10.1182\/blood-2011-06-359224.","journal-title":"Blood"},{"key":"1761_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.trsl.2018.05.009","volume":"200","author":"T Gremmel","year":"2018","unstructured":"Gremmel\u00a0T, Gisslinger\u00a0B, Gisslinger\u00a0H, Panzer\u00a0S. Response to aspirin therapy in patients with myeloproliferative neoplasms depends on the platelet count. 1. Transl Res. 2018;200:35\u201342. https:\/\/doi.org\/10.1016\/j.trsl.2018.05.009.","journal-title":"Transl Res"},{"issue":"8","key":"1761_CR35","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3324\/haematol.2016.146654","volume":"101","author":"A Alvarez-Larr\u00e1n","year":"2016","unstructured":"Alvarez-Larr\u00e1n\u00a0A, Pereira\u00a0A, Guglielmelli\u00a0P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a\u00a0CALR mutation. Haematologica. 2016;101(8):926\u201331. https:\/\/doi.org\/10.3324\/haematol.2016.146654.","journal-title":"Haematologica"},{"key":"1761_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2016.11.011","volume":"41","author":"A Rottenstreich","year":"2017","unstructured":"Rottenstreich\u00a0A, Kleinstern\u00a0G, Krichevsky\u00a0S, Varon\u00a0D, Lavie\u00a0D, Kalish\u00a0Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med. 2017;41:49\u201354. https:\/\/doi.org\/10.1016\/j.ejim.2016.11.011.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"1761_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison\u00a0CN, Campbell\u00a0PJ, Buck\u00a0G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N\u00a0Engl J Med. 2005;353(1):33\u201345.","journal-title":"N Engl J Med"},{"issue":"6","key":"1761_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/ejh.12759","volume":"97","author":"V Buxhofer-Ausch","year":"2016","unstructured":"Buxhofer-Ausch\u00a0V, Steurer\u00a0M, Sormann\u00a0S, et al. Influence of platelet and white blood cell counts on major thrombosis\u2014analysis from a\u00a0patient registry in essential thrombocythemia. Eur J Haematol. 2016;97(6):511\u20136. https:\/\/doi.org\/10.1111\/ejh.12759.","journal-title":"Eur J Haematol"},{"key":"1761_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13070","author":"V Buxhofer-Ausch","year":"2018","unstructured":"Buxhofer-Ausch\u00a0V, Steurer\u00a0M, Sormann\u00a0S, et al. Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. Eur J Haematol. 2018; https:\/\/doi.org\/10.1111\/ejh.13070.","journal-title":"Eur J Haematol"},{"issue":"29","key":"1761_CR40","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","volume":"29","author":"JJ Kiladjian","year":"2011","unstructured":"Kiladjian\u00a0JJ, Chevret\u00a0S, Dosquet\u00a0C, Chomienne\u00a0C, Rain\u00a0JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a\u00a0randomized trial initiated in 1980. J\u00a0Clin Oncol. 2011;29(29):3907\u201313. https:\/\/doi.org\/10.1200\/JCO.2011.36.0792.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1761_CR41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.leukres.2015.03.014","volume":"39","author":"G Tortorella","year":"2015","unstructured":"Tortorella\u00a0G, Piccin\u00a0A, Tieghi\u00a0A, et\u00a0al. Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study. Leuk Res. 2015;39(6):592\u20138. https:\/\/doi.org\/10.1016\/j.leukres.2015.03.014.","journal-title":"Leuk Res"},{"issue":"8639","key":"1761_CR42","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S0140-6736(89)92142-9","volume":"1","author":"H Gisslinger","year":"1989","unstructured":"Gisslinger\u00a0H, Ludwig\u00a0H, Linkesch\u00a0W, Chott\u00a0A, Fritz\u00a0E, Radaszkiewicz\u00a0T. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet. 1989;1(8639):634\u20137.","journal-title":"Lancet"},{"issue":"1","key":"1761_CR43","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1586\/ehm.12.69","volume":"6","author":"RT Silver","year":"2013","unstructured":"Silver\u00a0RT, Kiladjian\u00a0JJ, Hasselbalch\u00a0HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. Expert Rev Hematol. 2013;6(1):49\u201358. https:\/\/doi.org\/10.1586\/ehm.12.69.","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"1761_CR44","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","volume":"37","author":"T Stauffer Larsen","year":"2013","unstructured":"Stauffer Larsen\u00a0T, Iversen\u00a0KF, Hansen\u00a0E, et\u00a0al. Long term molecular responses in a\u00a0cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res. 2013;37(9):1041\u20135. https:\/\/doi.org\/10.1016\/j.leukres.2013.06.012.","journal-title":"Leuk Res"},{"issue":"11","key":"1761_CR45","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/leu.2008.280","volume":"22","author":"JJ Kiladjian","year":"2008","unstructured":"Kiladjian\u00a0JJ, Chomienne\u00a0C, Fenaux\u00a0P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia. 2008;22(11):1990\u20138. https:\/\/doi.org\/10.1038\/leu.2008.280.","journal-title":"Leukemia"},{"issue":"15","key":"1761_CR46","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger\u00a0H, Zagrijtschuk\u00a0O, Buxhofer-Ausch\u00a0V, et al. Ropeginterferon alfa-2b, a\u00a0novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139. https:\/\/doi.org\/10.1182\/blood-2015-04-637280.","journal-title":"Blood"},{"issue":"3","key":"1761_CR47","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger\u00a0H, Klade\u00a0C, Georgiev\u00a0P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a\u00a0randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013e208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4.","journal-title":"Lancet Haematol"},{"issue":"16","key":"1761_CR48","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi\u00a0A, Guglielmelli\u00a0P, Larson\u00a0DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313. https:\/\/doi.org\/10.1182\/blood-2014-05-579136. quiz 2615.","journal-title":"Blood"},{"key":"1761_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24788","author":"G Jeryczynski","year":"2017","unstructured":"Jeryczynski\u00a0G, Thiele\u00a0J, Gisslinger\u00a0B, et al. Pre-fibrotic\/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017; https:\/\/doi.org\/10.1002\/ajh.24788.","journal-title":"Am J Hematol"},{"issue":"6","key":"1761_CR50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti\u00a0F, Thiele\u00a0J, Girodon\u00a0F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a\u00a0study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197\u2013201. https:\/\/doi.org\/10.1182\/blood-2012-01-403279.","journal-title":"Blood"},{"issue":"4 Pt 2","key":"1761_CR51","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-2006-942763","volume":"32","author":"M Griesshammer","year":"2006","unstructured":"Griesshammer\u00a0M, Struve\u00a0S, Harrison\u00a0CM. Essential thrombocythemia\/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost. 2006;32(4 Pt 2):422\u20139.","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"1761_CR52","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/17474086.2018.1506325","volume":"11","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer\u00a0M, Sadjadian\u00a0P, Wille\u00a0K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697\u2013706. https:\/\/doi.org\/10.1080\/17474086.2018.1506325.","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"1761_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1538-7836.2009.03686.x.Epub","volume":"8","author":"F Passamonti","year":"2010","unstructured":"Passamonti\u00a0F, Rumi\u00a0E, Randi\u00a0ML, Morra\u00a0E, Cazzola\u00a0M. Aspirin in pregnant patients with essential thrombocythemia: a\u00a0retrospective analysis of 129 pregnancies. J\u00a0Thromb Haemost. 2010;8(2):411\u20133. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03686.x.Epub.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1761_CR54","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.blre.2008.03.007","volume":"22","author":"M Griesshammer","year":"2008","unstructured":"Griesshammer\u00a0M, Struve\u00a0S, Barbui\u00a0T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22(5):235\u201345. https:\/\/doi.org\/10.1016\/j.blre.2008.03.007.","journal-title":"Blood Rev"},{"issue":"5","key":"1761_CR55","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.3324\/haematol.2015.139691","volume":"101","author":"Y Beauverd","year":"2016","unstructured":"Beauverd\u00a0Y, Radia\u00a0D, Cargo\u00a0C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica. 2016;101(5):e182\u2013e4. https:\/\/doi.org\/10.3324\/haematol.2015.139691.","journal-title":"Haematologica"},{"issue":"1","key":"1761_CR56","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/hematology.2019001318","volume":"2019","author":"BL Stein","year":"2019","unstructured":"Stein\u00a0BL, Martin\u00a0K. From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2019;2019(1):397\u2013406. https:\/\/doi.org\/10.1182\/hematology.2019001318.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1761_CR57","unstructured":"NCCN. NCCN clinical practice guidelines in oncology (NCCN Guidelines) for myeloproliferative neoplasms, version 2.2019. 2019. www.nccn.org. Accessed 24 June 2019."}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-020-01761-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01761-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T11:32:17Z","timestamp":1611747137000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-020-01761-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":57,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01761-3","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.\u00a0Buxhofer-Ausch, S.\u00a0Heibl, T.\u00a0Sliwa, C.\u00a0Beham-Schmid, D.\u00a0Wolf, K.\u00a0Geissler, M.T.\u00a0Krauth, P.\u00a0Krippl, A.\u00a0Petzer, A.\u00a0W\u00f6lfler, T.\u00a0Melchardt, and H.\u00a0Gisslinger declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}